SyMRI 3D is designed to improve diagnostic outcomes by providing high-resolution, rich quantitative data in 3D, including quantitative values, accurate segmentation, and adjustable contrasts.  A prospective, multi-center, multi-reader clinical investigation to evaluate the diagnostic performance of SyMRI 3D images to conventional 3D MRI has shown the capability to replace conventional 3D imaging, improving both efficiency and throughput.  

This strategically important move is aligned with SyntheticMR's recent acquisition of Combinostics and is expected to create synergies.  The release of SyMRI 3D is the first step in the process enabling the combination of SyntheticMR's ability to provide brain tissue characterization with Combinostics' segmentation algorithms, offering unique insights into automatically parcellated brain structures and segmented lesions, particularly related to neurodegenerative diseases such as MS and dementia. 

"The regulatory approval in Japan serves as solid confirmation of our established track record and underscores our commitment to deepening our engagement with the healthcare community in the region," stated Johanna Norén, Acting CEO of SyntheticMR.  

This regulatory milestone underscores SyntheticMR's dedication to the Japanese market and is expected to drive continued growth and increased adoption of our innovative solutions.